Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric ravulizumab in generalized myasthenia gravis
NL-OMON60857Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ravulizumab in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Primary endpoints: Ravulizumab concentration and Serum free C5. Started Jun 2023; status: completed.
02
Drugs
ravulizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON60857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60857.